Literature DB >> 10868944

Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity.

A Basu1, R Basu, P Shah, A Vella, C M Johnson, K S Nair, M D Jensen, W F Schwenk, R A Rizza.   

Abstract

Insulin-induced stimulation of muscle glucose uptake (MGU) is impaired in people with type 2 diabetes. To determine whether insulin-induced stimulation of splanchnic glucose uptake (SGU) is also impaired, we simultaneously measured leg glucose uptake (LGU) and SGU in 14 nondiabetic subjects and 16 subjects with type 2 diabetes using a combined organ catheterization-tracer infusion technique. Glucose was clamped at approximately 9.3 mmol/l, while insulin concentrations were maintained at approximately 72 pmol/l (low) and approximately 150 pmol/l (high) for 3 h each. Endogenous hormone secretion was inhibited with somatostatin. Total body glucose disappearance was lower (P < 0.01) and glucose production higher (P < 0.01) during both insulin infusions in the diabetic compared with the nondiabetic subjects, indicating insulin resistance. Splanchnic glucose production was higher (P < 0.05) in the diabetic subjects during the low but not the high insulin infusion. SGU was slightly lower in the diabetic than in the nondiabetic subjects during the low insulin infusion and 50-60% lower (P < 0.05) during the high insulin infusion. LGU (P < 0.001), but not SGU, was inversely correlated with the degree of visceral adiposity. The contribution of the indirect pathway to hepatic glycogen synthesis did not differ in the diabetic and nondiabetic subjects. In contrast, both flux through the UDP-glucose pool (P < 0.05) and the contribution of the direct pathway to glycogen synthesis (P < 0.01) were lower in the diabetic than in the nondiabetic subjects, indicating decreased uptake and/or phosphorylation of extracellular glucose. On the other hand, glycogenolysis was equally suppressed in both groups. In summary, type 2 diabetes impairs the ability of insulin to stimulate both MGU and SGU. The defect appears to reside at a proximal (e.g., glucokinase) metabolic step and is not related to the degree of visceral adiposity. These data suggest that impaired hepatic glucose uptake as well as MGU contribute to hyperglycemia in people with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10868944     DOI: 10.2337/diabetes.49.2.272

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  60 in total

1.  Non-esterified fatty acids impair insulin-mediated glucose uptake and disposition in the liver.

Authors:  P Iozzo; R Lautamaki; F Geisler; K A Virtanen; V Oikonen; M Haaparanta; H Yki-Jarvinen; E Ferrannini; J Knuuti; P Nuutila
Journal:  Diabetologia       Date:  2004-07-09       Impact factor: 10.122

Review 2.  Alterations of glucose metabolism in type 2 diabetes mellitus. An overview.

Authors:  Riccardo C Bonadonna
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

3.  Insulin:Carbohydrate Ratio--Part of the Story.

Authors:  Ananda Basu; Rita Basu
Journal:  Diabetes Technol Ther       Date:  2015-12       Impact factor: 6.118

4.  Metabolic fuel selection: the importance of being flexible.

Authors:  Perry E Bickel
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

5.  Effects of type 2 diabetes and insulin on whole-body, splanchnic, and leg protein metabolism.

Authors:  Kevin R Short; Brian A Irving; Ananda Basu; C Michael Johnson; K Sreekumaran Nair; Rita Basu
Journal:  J Clin Endocrinol Metab       Date:  2012-10-02       Impact factor: 5.958

6.  GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization.

Authors:  Ko Kotani; Odile D Peroni; Yasuhiko Minokoshi; Olivier Boss; Barbara B Kahn
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

7.  Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes.

Authors:  D J Baker; A M Atkinson; G P Wilkinson; G J Coope; A D Charles; B Leighton
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

8.  Hepatic 11β-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique.

Authors:  Simmi Dube; Barbara Norby; Vishwanath Pattan; Ravi K Lingineni; Ravinder J Singh; Rickey E Carter; Ananda Basu; Rita Basu
Journal:  Diabetologia       Date:  2014-04-26       Impact factor: 10.122

9.  Liver is the site of splanchnic cortisol production in obese nondiabetic humans.

Authors:  Rita Basu; Ananda Basu; Meagan Grudzien; Paul Jung; Peer Jacobson; Michael Johnson; Ravinder Singh; Michael Sarr; Robert A Rizza
Journal:  Diabetes       Date:  2008-10-13       Impact factor: 9.461

10.  Metabolic adaptations to HFHS overfeeding: how whole body and tissues postprandial metabolic flexibility adapt in Yucatan mini-pigs.

Authors:  Sergio Polakof; Didier Rémond; Annick Bernalier-Donadille; Mathieu Rambeau; Estelle Pujos-Guillot; Blandine Comte; Dominique Dardevet; Isabelle Savary-Auzeloux
Journal:  Eur J Nutr       Date:  2016-08-27       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.